This paper presents the economic rationale for treating Common Goods for Health (CGH) as priorities for public intervention. We use the concept of market failure as a central argument for identifying CGH and apply cost-effectiveness analysis (CEA) as a normative tool to prioritize CGH interventions in public finance decisions. We show that CGH are consistent with traditional lists of public health core functions but cannot be identified separately from non-CGH activities in such lists. We propose a public finance decision tree, adapted from existing health economics tools, to identify CGH activities within the set of cost-effective interventions for the health sector. We test the framework by applying it to the 2018 Disease Control Priority (DCP) list of interventions recommended for public funding and find that less than 10% of cost-effective interventions unconditionally qualify as CGH, while another two-thirds may or may not qualify depending on context and form. We conclude that while CEA can be used as a tool to prioritize CGH, the scarcity of such analyses for CGH interventions may be partly responsible for the lack of priority given to them. We encourage further research to address methodological and resource challenges to assessing the cost-effectiveness of CGH intervention packages, in particular those involving large investments and long-term benefits.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/23288604.2019.1656028 | DOI Listing |
Biol Methods Protoc
December 2024
Division of Molecular Medicine, St John's Research Institute, St John's National Academy of Health Sciences (a Unit of CBCI Society for Medical Education), Bangalore 560034, Karnataka, India.
Real time-polymerase chain reaction (RT-PCR) is used routinely in clinical practice as a cost-effective method for molecular diagnostics. Research in pediatric B-cell Acute Lymphoblastic Leukemia (ped B-ALL) suggests that apart from cytogenetics and clinical features, there is a need to include Copy number variation (CNV) in select genes at diagnosis, for upfront stratification of patients. Using ped B-ALL as a model, we have developed a RT-PCR-based iterative probability scoring method for reporting CNVs, and relative gene-expression changes.
View Article and Find Full Text PDFJ Cosmet Dermatol
January 2025
CGH Compagnie Generale des Hopitaux, Rome, Italy.
Introduction: In recent years, the field of aesthetic dermatology has witnessed a surge in demand for minimally invasive procedures aimed at rejuvenating aging skin. This study aims to address this demand by evaluating the effectiveness of the injectable gel in rejuvenating aging skin, particularly by targeting collagen regeneration and lifting effect.
Materials And Methods: The study involved 43 participants who underwent three monthly injection sessions targeting retaining ligaments.
Taiwan J Obstet Gynecol
January 2025
Department of Obstetrics and Gynecology, Changhua Christan Hospital, Changhua, Taiwan. Electronic address:
Objective: Prenatal diagnosis of fetal 13q34 microdeletion is a rare condition, which may present with abnormal fetal development, including facial dysmorphism, mental retardation, and developmental delay. We present a pregnant woman in whom the fetus presented with a 0.24-cm ventricular septal defect at 20 weeks of gestation, with fetal 13q34 (113610612-115092648) deletion.
View Article and Find Full Text PDFKardiol Pol
January 2025
Department of Preventive Cardiology and Lipidology, Medical University of Lodz, Łódź, Poland.
Cardiovascular disease (CVD) remains a leading cause of morbidity and mortality worldwide with 20 million deaths annually. Recent advances in both primary and secondary prevention strategies have shown promising results in reducing the incidence and recurrence of cardiovascular events, but a question of fundamental importance is whether we are effective enough when predicting risk only in those over 40 years of age and only for 10 years. A similarly important question concerns the pathophysiological border between primary and secondary prevention and whether we should reorient our focus to atherosclerosis prevention as a continuous process that becomes clinically apparent later in life.
View Article and Find Full Text PDFPharmaceuticals (Basel)
December 2024
Department of Anesthesiology, Cathay General Hospital, Taipei 106, Taiwan.
Background: Morphine analgesic tolerance (MAT) limits the clinical application of morphine in the management of chronic pain. IIK7 is a melatonin type 2 (MT2) receptor agonist known to have antioxidant properties. Oxidative stress is recognized as a critical factor in MAT.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!